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HLA and the Human Genome Project
Shortly  before  he  passed  away  last  year,  the  late  Jean 
Dausset  said  he  wanted  to  be  remembered  for  four 
disciplines  to  which  he  had  made  significant  contri­
butions: anthropology, immune response, transplantation 
and predictive medicine [1]. All of these were based on 
his seminal discovery of the human leukocyte antigens 
(HLA) in the 1950s. In 1980 he received the Nobel Prize 
in Physiology or Medicine jointly with Baruj Benacerraf 
and  George  Snell  ‘for  their  discoveries  concerning 
genetically determined structures on the cell surface that 
regulate immunological reactions’.
Through  the  international  and  highly  collaborative 
HLA workshops that he pioneered with colleagues in the 
1960s  and  which  have  been  running  successfully  ever 
since,  Jean  Dausset  and  his  colleagues  established  the 
important role of the histocompatibility antigens in the 
control of the immune response and in the susceptibility 
or resistance to a wide variety of diseases, including those 
with an auto­immune component, and they realized that 
these  defined  a  key  element  of  the  biologically  unique 
identities  of  individuals.  The  major  histocompatibility 
complex (MHC), in which the genes encoding the HLA 
antigens are located, turned out to be a high gene density, 
high diversity and low recombination genetic system that 
has evolved to become a master coordinator of individual 
specificity in both innate and cognate immunity [2]. The 
highly polymorphic nature of the HLA antigens, initially 
detected through serological and cellular assays with the 
active participation of blood and organ transplantation 
donors,  was  exploited  early  on  to  analyze  the  genetics 
and  migration  history  of  human  populations.  Under­
standing the susceptibility or resistance to diseases and 
infections thus laid an early cornerstone for the creation 
of  predictive  medicine  through  personalized  disease 
prevention.
These contributions expanded in scope and depth with 
the  biochemical  and  functional  characterization  of  the 
MHC  antigens  expressed  on  a  variety  of  cell  types, 
particularly within the immune system. With the cloning 
and  sequencing  of  the  human  and  murine  histocom­
patibility genes in the early 1980s, the characterization of 
the HLA and H­2 loci became test cases that contributed 
to  demonstrating  the  feasibility  and  value  of  genome 
projects, as they were the first multi­megabase genetic 
loci to be sequenced entirely, defining for the first time all 
of  the  genes  in  this  gene­rich  region  as  well  as  also 
providing a wealth of polymorphic markers for genetic 
linkage  studies.  This  definition  of  all  the  genes  in  an 
impor  tant region through discovery science by sequen­
cing  a  chromosomal  region  was  the  forerunner  of  the 
pioneering  contribution  the  genome  project  made  in 
essentially defining all of the genes of the human genome 
(and making them available to all scientists). We believe 
that it is important to take advantage of the lessons of the 
HLA/H­2 saga to enable effective and efficient deploy­
ment of the systems medicine roadmap [3,4].
Technological  development  is  essential  for  high 
throughput, high precision and low cost data generation 
[5].  The  initially  lengthy  and  cumbersome  serological, 
cellular, biochemical and genetic HLA typing assays have 
greatly  benefited  from  laboratory  automation  and  are 
conducted  under  standard  operating  procedures  in 
centralized  facilities  in  compliance  with  regulatory 
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professional accreditation schemes were developed very 
early on by the HLA community to become the profes­
sional  platform  of  histocompatibility  medicine  world­
wide. This has been instrumental in setting the frame­
work  for  the  Human  Genome  Project,  in  which  many 
MHC scientists were involved. Rapid and striking recent 
advances  in  high  throughput  and  low  cost  sequencing 
technology are now providing access to the exponential 
characterization  of  individual  genomes  and  transcrip­
tomes, enabling, for example, systems genetics approaches 
for  the  identification  of  disease­related  genes  and 
polymorphisms  [6].  Moreover,  there  are  now  exciting 
possibilities for analyzing autoimmune diseases, allergies 
and transplantation biology in powerful new assays, such 
as sequencing the MHC locus from family members to 
delineate  MHC  genes  and  their  linkage  relationships, 
using protein chips that contain more than half of the 
human proteins to search for autoantibodies in sera, or 
the  ascertainment  of  the  complete  repertoires  of 
functional  antibody  molecules  in  B  cells  and  T­cell 
receptors in T cells. Together these new dimensions of 
exploring  patient  data  open  up  new  and  unique 
opportunities for attacking immune­related diseases. In 
order to unravel with a similar coverage and depth the 
role of other key biomolecules, such as proteins, lipids, 
sugars and other metabolites, groundbreaking innovative 
technological developments will be necessary.
HLA and systems biology
The generation and management of massive amounts of 
sequence  information  are  becoming  dematerialized 
commodities based on community­agreed standards and 
reagents. This follows a trend that was established early 
on  in  the  HLA  community  with  the  nomenclature 
committees  and  the  provision  of  sets  of  standardized 
reference reagents for common use in the HLA work­
shops. This has the merit of refocusing attention on the 
definition of precise biological and medical questions and 
the  identification  of  appropriate  biological  resources, 
which are the necessary starting points of any successful 
systems  biology  approaches.  In  this  context,  public­
private  partnerships  based  on  well  characterized  and 
openly shared biological resources and data repositories, 
taking into account issues of intellectual property rights 
and active patient participation, individually and through 
patient organizations, are vitally important [7]. The pre­
competitive  Innovative  Medicines  Initiative,  a  joint 
under  taking  of  the  European  Union  and  the  European 
Federation of Pharmaceutical Industry Associations [8], 
and the Program on Public­Private Partnerships of the 
United States National Institutes of Health Roadmap [9] 
are initial examples of these developments. They should 
be encouraged to expand and network on a worldwide 
basis  in  the  same  spirit  as  the  HLA  workshops,  with 
active  participation  of  technology  providers,  patient 
organizations and regulatory authorities.
Analysis of the sequence, polymorphism, transcription 
and protein­expression profiles of various MHCs and of 
the three­dimensional structure of the histocompatibility 
antigens have required and triggered the development of 
a wide variety of computational tools for data collection, 
storage  and  analysis.  They  enabled  elucidation  of 
structure­function  relationships  of  the  encoded  cell 
surface  antigens,  illuminating  their  ability  to  bind  and 
present foreign peptides to immune effector cells. They 
also  provided  the  computational  framework  for  the 
forma  tion of electronic public repositories, which have 
been greatly expanded with the advent of genomics. The 
development in the recent years of increasingly powerful 
computational  resources  is  proving  essential  for 
maintaining  the  ability  to  access  and  analyze  the 
exponentially  increasing  flow  of  diverse  data  types  on 
biomolecules,  cells,  organs  and  the  associated  normal 
and  pathological  phenotypes.  Their  implementation  in 
computer  grids  is  providing  computing­on­demand 
cloud­based  resources  that  can  be  managed  externally, 
enabling  researchers  to  focus  their  attention  on  the 
development and use of mathematical and computational 
tools. The tools required for the successful application of 
these  computational  resources  to  biomedical  problems 
are  complex  because  systems  biology  approaches 
typically  involve  iterative  cycles  of  experiment  and 
modeling [10,11].
The challenge of the 21st century for all scientific and 
engineering disciplines is understanding and managing 
complexity. In this context, biology is unique in having 
initiated  the  development  of  powerful  tools  to  attack 
biological complexity, such as systems approaches to the 
control of physiology, development and complex disease 
[12­14]. Emerging high throughput biological tools are 
driven  by  the  emergence  of  microfluidics  and  nano­
technology  and  by  the  biology­driven  creation  of 
powerful  and  novel  computational  and  mathematical 
tools. This raises the possibility that biology will dominate 
21st  century  science  in  part  because  it  holds  the 
technological  capability  to  attack  some  of  the  most 
fundamental  problems  of  humankind,  such  as  global 
healthcare  and  well­being,  energy  and  environmental 
management, sustainable agriculture and nutrition.
HLA and systems medicine
Hematopoietic  stem  cell  and  organ  transplantation 
represent a unique opportunity to study the complex and 
systemic  effects  of  introducing  a  new  genome  in  an 
individual.  The  drastic  biological  perturbations  caused 
depend on both the genetic make­up of the donor and 
that of the recipient. Donor­recipient histocompatibility 
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logical effects, thus identifying the genetic contribution 
of MHC alleles, haplotypes and their combinations. This 
opens  up,  for  example,  the  possibility  of  neutralizing 
MHC  genetic  differences  by  performing  hematopoietic 
stem cell transplantation between identical siblings. Such 
a clinical setting makes it possible to highlight the effects 
of  other  immunogenetic  systems,  such  as  the  minor 
histocompatibility  loci,  which  have  a  more  limited  yet 
significant influence on the outcome of transplantation 
[15]. Once again the genome project has transformed the 
search for the genes encoding minor histocompatibility 
loci through its complete parts list of all human genes. 
There is a strong incentive to develop and validate cell 
therapeutics using allogeneic cells and/or tissues to treat 
chronic  diseases  and  aging.  The  experience  gained  in 
transplantation medicine will directly benefit regenera  tive 
medicine by fostering an integrated approach of biology, 
medicine, logistics, and regulatory and social issues.
Among  the  major  bottlenecks  in  translating  systems 
biology into systems medicine are the limited number of 
clinical cases that can be included in randomized trials 
and the number of genetic, environmental and nutritional 
variables  that  cannot  be  easily  accounted  for.  Trans­
plantation medicine has been confronted with this issue 
from the beginning of its development. Validation of the 
role  of  each  individual  HLA  locus  was  established 
sequentially  by  comparing  populations  of  patients  of 
different but known genetic composition (monozygotic 
twins, siblings, haplotype­matched family members and 
HLA­matched  unrelated  individuals).  This  has  been 
instrumental in deciphering the role of the different HLA 
loci, alleles or haplotypes. With the increasing number of 
genetic  systems  and  alleles  that  have  to  be  taken  into 
account,  the  availability  of  real  patients  is  limited  and 
insufficient.  This  triggers  the  need  to  develop  virtual 
patient  models  that  mimic  the  patients’  main  charac­
teristics,  from  which  testable  hypotheses  can  be 
generated and validated on the small number of actual 
patients available.
In addition to transplantation and regenerative medi­
cine,  other  important  diseases,  such  as  auto­immune 
diseases for which HLA has been confirmed as the major 
genetic factor, could benefit from an HLA­based systems 
biology  approach.  Insulin­dependent  diabetes  mellitus, 
rheumatoid arthritis, ankylosing spondylitis and multiple 
sclerosis  are  among  the  first  obvious  candidates. 
Moreover,  given  that  recent  genome­wide  association 
studies  have  revealed  a  rather  unexpected  immune 
component in psychiatric disorders such as schizophrenia 
[16], these could also be amenable to the same approach. 
The complexity of the HLA system has led us right into 
the complexities of predictive, preventive, personalized 
and participatory (P4) medicine.
Looking into the future, on the basis of its past history, 
we can be certain of at least one thing: the HLA system 
will  continue  to  have  a  pivotal  integrative  role  in  the 
advent  of  P4  medicine  and  should  therefore  be  con­
sidered as a hallmark of systems medicine.
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